Is semaglutide legal for clinical use, compounding, or research? The short answer: it depends on the latest FDA reclassification and enforcement priorities. As of this month, semaglutide (brands: Ozempic, Wegovy, Rybelsus) remains FDA-approved for diabetes and weight management, but its legal status for compounding pharmacies and research peptides is under active regulatory review. PeptidesBeat tracks these shifts daily — because for clinics and researchers, staying ahead of reclassification is critical.
The FDA maintains a drug shortage list that directly impacts compounding legality. When semaglutide is in shortage, compounding pharmacies can legally produce copies under certain conditions. However, once the shortage resolves, bulk compounding may become restricted. The question "is semaglutide legal" often hinges on these shortage status updates. We monitor FDA enforcement discretion letters and reclassification notices so you don't have to.
For researchers, semaglutide is legal to acquire from registered suppliers for preclinical or clinical trials under an IND. Yet unapproved peptide sources may fall into a gray area. PeptidesBeat provides daily dig